RayKnowChina Research Map
Shortlist

University of Electronic Science and Technology of China

电子科技大学

ChengduUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
1.2%Leads about 1 in 82 of China's research papers on NPC

Led 29 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
2
Research papers it led
29
Trials it led
6
Share of China's trials
1.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 442025
ThemesRadiotherapy techniqueImaging & AIRecurrent / metastatic disease

Hospitals counted here

  1. Sichuan Cancer Hospital25
  2. Sichuan Provincial People's Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Evaluation of the efficacy of the anti-ulcer oral mucosal protective agent RADoralex® in the prevention and treatment of radiation-induced oral mucosal reactions induced during treatment of nasopharyngeal carcinoma.2022Cancer biology & therapyRCTFree full text
  2. Short-course PD-1 blockade in locally advanced nasopharyngeal carcinoma: a phase II randomized trial protocol (Tori-013).2025Frontiers in immunologyFree full text
  3. Early prediction of parotid glands secretory function based on ADC variations during radiotherapy for nasopharyngeal carcinoma: a phase II prospective study.2025Radiation oncology (London, England)Free full text
  4. Correlation between taste and smell alterations and quality of life in patients treated with radiotherapy for nasopharyngeal carcinoma: a cross-sectional study in China.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerFree full text
  5. MB based RT-qPCR increase the clinical application of cfEBV DNA for NPC in non-endemic area of China.2025Scientific reportsFree full text
Trials on ClinicalTrials.gov6
  1. A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07062484Lead sponsorN/AStart 2025-07
  2. Nituzumab (Taixinsheng ®) A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT05508347Lead sponsorPhase 2Start 2022-04
  3. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  4. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Study sitePhase 1/Phase 2Start 2025-11
  5. Individualized Neck Cervical Irradiation Prophylaxis Trial of NPCRecruitingNCT07303023Study sitePhase 3Start 2025-09
  6. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyRecruitingNCT06839066Study sitePhase 2Start 2025-04

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
1.9%Leads about 1 in 53 of China's research papers on ESCC ▲ from 0.8%

Led 55 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
1
Research papers it led
55
Trials it led
17
Share of China's trials
3.0%
Share of the world's papers
1.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesNeoadjuvant & combined treatmentSurgeryRadiotherapy

Hospitals counted here

  1. Sichuan Cancer Hospital50
  2. Sichuan Provincial People's Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Fluorescence quantitative assessment of blood perfusion in the gastric conduit to reduce anastomotic leakage after esophagectomy: a randomized controlled trial.2025Surgical endoscopyRCT
  2. Involved-Field Irradiation Versus Elective Nodal Irradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemoradiotherapy.2025Cancer medicineFree full text
  3. Long-term outcomes of minimally invasive esophagectomy vs. open esophagectomy in older patients with esophageal squamous cell carcinoma: a propensity score matching analysis.2025Langenbeck's archives of surgeryFree full text
  4. Real-world efficacy of PD-1 inhibitors in treating oesophageal squamous cell carcinoma (ESCAPE): protocol of a multicentre, real-world, observational, cohort study.2025BMJ openFree full text
  5. Enhanced prognosis prediction model in esophageal cancer via lymph node assessment post-neoadjuvant.2025BMC cancerFree full text
Trials on ClinicalTrials.gov6
  1. Sintilimab Plus NCT or NCRT Versus NCRT for ESCCNot yet recruitingNCT05244798Lead sponsorPhase 3Start 2022-11
  2. Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCRecruitingNCT07733830Study sitePhase 2Start 2026-07
  3. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  4. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  5. Development and Validation of a Survival Prediction Model for Esophageal Cancer Patients After EsophagectomyCompletedNCT06169930Lead sponsorStart 2023-12
  6. Clinical Value and Efficacy Index of Lymphadenectomy for Thoracic EsccCompletedNCT05604664Lead sponsorStart 2022-05

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.4%Leads under 1 in 100 of China's research papers on HCC

Led 67 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
1
Research papers it led
67
Trials it led
3
Share of China's trials
0.2%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesRecurrence & prognosisImmunotherapy & targeted drugsLocal treatment (ablation, TACE, HAIC)

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Sichuan Provincial People's Hospital42
  2. Sichuan Cancer Hospital19
  3. Mianyang Central Hospital, University of Electronic Science2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Regorafenib Combination Therapy in Advanced Hepatocellular Carcinoma: With or without Transarterial Chemoembolization.2025Oncology
  2. Preoperative TACE with PD-1 inhibitors and TKIs in beyond "up-to-seven" hepatocellular carcinoma: a propensity score matched analysis.2025Frontiers in immunologyFree full text
  3. Efficacy and safety of postoperative adjuvant HAIC combining lenvatinib with or without PD-1 inhibitors in solitary large HCC: A multicenter retrospective study.2025Frontiers in immunologyFree full text
  4. Predicting tumor response to TACE plus lenvatinib and PD-1 inhibitors for unresectable HCC: A multicenter observational study.2025European journal of radiology
  5. Efficacy and safety of radiotherapy combined with immune checkpoint inhibitors for advanced or unresectable hepatocellular carcinoma: A systematic review and meta-analysis.2025Critical reviews in oncology/hematology
Trials on ClinicalTrials.gov6
  1. TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular CarcinomaRecruitingNCT06485466Lead sponsorPhase 3Start 2024-08
  2. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  3. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  4. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionRecruitingNCT06560827Study sitePhase 1Start 2023-10
  5. TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCCCompletedNCT04518852Lead sponsorPhase 2Start 2020-09
  6. CMRA for US-guided-MWA of Liver TumorsStatus unknownNCT05990257Lead sponsorN/AStart 2018-07

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.4%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 39 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
0
Research papers it led
39
Trials it led
1
Share of China's trials
0.07%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesSurgeryEarly detection & endoscopyImaging & AI

Hospitals counted here

  1. Sichuan Provincial People's Hospital24
  2. Sichuan Cancer Hospital13
  3. Mianyang Central Hospital, University of Electronic Science1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Impacts of omega-3 fatty acids intervention on immune functions and clinical outcomes in surgical gastric cancer patients: a systematic review and trial sequential meta-analysis.2025BMC cancerFree full text
  2. Prenatal and Postnatal Ultrasonographic Characteristics of Immature Teratoma in the Gastric Wall: A Case Report.2025Journal of clinical ultrasound : JCU
  3. Disparities in overall survival of gastric cancer patients after radical gastrectomy: an age and rural-urban residence-based cohort study with propensity score matching analysis.2025Scientific reportsFree full text
  4. Dual-phase contrast-enhanced CT-based intratumoral and peritumoral radiomics for preoperative prediction of lymph node metastasis in gastric cancer.2025BMC gastroenterologyFree full text
  5. Dual-phase contrast-enhanced CT-based intratumoral and peritumoral radiomics for preoperative prediction of lymphovascular invasion in gastric cancer.2025BMC medical imagingFree full text
Trials on ClinicalTrials.gov6
  1. Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerRecruitingNCT07392892Study sitePhase 2/Phase 3Start 2026-05
  2. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  3. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingNCT06901531Study sitePhase 3Start 2025-05
  4. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  5. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  6. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06155383Study sitePhase 2Start 2023-11

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.3%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 7 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Sichuan Provincial People's Hospital6

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
1.1%Leads about 1 in 87 of China's research papers on Gastrointestinal stromal tumour ▲ from 0.5%

Led 6 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
1
Share of China's trials
1.4%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 3320242025: 002025

Hospitals counted here

  1. Sichuan Cancer Hospital3
  2. Sichuan Provincial People's Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.3%Leads under 1 in 100 of China's research papers on Neuroblastoma New since 2021

Led 3 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.07%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Sichuan Provincial People's Hospital2
  2. Sichuan Cancer Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
1.0%Leads about 1 in 99 of China's research papers on Myeloma ▲ from 0.1%

Led 17 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
17
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 1120242025: 112025
ThemesDiagnosis, MRD & riskDrug combinationsRelapse & resistance

Hospitals counted here

  1. Sichuan Provincial People's Hospital13
  2. Mianyang Central Hospital, University of Electronic Science3
  3. Mianyang Central Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Efficacy Analysis of Bortezomib Combined with Lenalidomide in Newly Diagnosed Multiple Myeloma with 1q21 Gain/Amp.2024Technology in cancer research & treatmentFree full text
  2. Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients.2023Clinical and experimental medicineFree full text
  3. A review on the treatment of multiple myeloma with small molecular agents in the past five years.2022European journal of medicinal chemistry
  4. Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.2021European journal of pharmacology
  5. Prognostic value of fatty acid metabolism-related signature and integrated analysis of the immune microenvironment in multiple myeloma.2025BMC cancerFree full text
Trials on ClinicalTrials.gov6
  1. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  2. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07663253Study siteStart 2026-06
  3. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07258511Study sitePhase 3Start 2026-02
  4. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  5. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  6. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
1.1%Leads about 1 in 91 of China's research papers on Haemophilia A New since 2021

Led 3 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
1.7%Leads about 1 in 61 of China's research papers on NMOSD New since 2021

Led 8 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025
ThemesAntibodies & diagnosisImagingAcute attack treatment

Hospitals counted here

  1. Sichuan Provincial People's Hospital7
  2. Sichuan Cancer Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
0.6%Leads under 1 in 100 of China's research papers on Myasthenia gravis

Led 3 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 332025
ThemesBiologic & complement drugsAntibodies & diagnosisThymus & thymectomy

Hospitals counted here

  1. Sichuan Provincial People's Hospital2
  2. Mianyang Central Hospital, University of Electronic Science1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
1.1%Leads about 1 in 88 of China's research papers on Anti-NMDA receptor encephalitis New since 2021

Led 3 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Sichuan Provincial People's Hospital2
  2. Mianyang Central Hospital, University of Electronic Science1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hepatic echinococcosis

肝包虫病
6.6%Leads about 1 in 15 of China's research papers on Hepatic echinococcosis

Led 10 of 152 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (32.2%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
2.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 222025

Hospitals counted here

  1. Sichuan Provincial People's Hospital10

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
2.0%Leads about 1 in 50 of China's research papers on Idiopathic pulmonary fibrosis ▲ from 1.4%

Led 20 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
20
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Sichuan Provincial People's Hospital17
  2. Sichuan Cancer Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Anxiety and depression status in patients with idiopathic pulmonary fibrosis and outcomes of nintedanib treatment: an observational study.2024Annals of medicine
  2. Identification of diagnostic and prognostic phospholipid biomarkers in idiopathic pulmonary fibrosis via machine learning and in vivo validation.2025Human genomics
  3. Machine learning identifies lipid-associated genes and constructs diagnostic and prognostic models for idiopathic pulmonary fibrosis.2025Orphanet journal of rare diseases
  4. Ferroptosis in idiopathic pulmonary fibrosis: mechanisms, impact, and therapeutic opportunities.2025Frontiers in immunology
  5. SIRT5-mediated desuccinylation prevents mitochondrial dysfunction in alveolar epithelial cells senescence and pulmonary fibrosis.2025Cellular signalling
Trials on ClinicalTrials.gov5
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07121413Study sitePhase 2Start 2025-11
  3. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  4. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  5. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Study sitePhase 2Start 2023-11

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.9%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis New since 2021

Led 7 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 442025

Hospitals counted here

  1. Sichuan Provincial People's Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
1.4%Leads about 1 in 74 of China's research papers on IgA nephropathy ▲ from 0.8%

Led 10 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
1
Research papers it led
10
Trials it led
1
Share of China's trials
0.9%
Share of the world's papers
0.6%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 222025

Hospitals counted here

  1. Sichuan Provincial People's Hospital10

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Clinicopathological characteristics and predictors of renal outcomes in diffuse crescentic glomerulonephritis : a retrospective single-center study from Western China.2025BMC nephrology
  2. The prognostic value of platelet-to-lymphocyte ratio on the long-term renal survival in patients with IgA nephropathy.2021International urology and nephrology
  3. Non-Invasive Early Detection of Tubular Atrophy and Interstitial Fibrosis in Immunoglobulin A Nephropathy Using [18F] AlF-NOTA-FAPI-04 PET/CT: A Pilot Study.2026Academic radiology
  4. Prevalence and trend of biopsy-proven IgA nephropathy in China: a systematic review.2025Journal of nephrology
  5. Long-term renal survival in patients with IgA nephropathy: a systematic review.2024Renal failure
Trials on ClinicalTrials.gov6
  1. A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA NephropathyRecruitingNCT06676007Lead sponsorStart 2024-10
  2. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  3. A Study of SGB-9768 in Patients With Complement-mediated Kidney DiseasesActive, not recruitingNCT06786338Study sitePhase 2Start 2025-06
  4. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruitingNCT06774664Study sitePhase 1/Phase 2Start 2025-01
  5. Relative Bioavailability Study of HR19042 in Healthy SubjectsCompletedNCT06922305Study sitePhase 1Start 2023-12
  6. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionActive, not recruitingNCT05797610Study sitePhase 3Start 2023-08

PubMed searchClinicalTrials.gov